Overview

Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)

Status:
Not yet recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC)

Phase:

Phase 2

Details

Lead Sponsor:

The University of Hong Kong

Collaborator:

Merck KGaA, Darmstadt, Germany